


Product Details

Catalog No.	ATAD00262
INN (International Nonproprietary Name)	Ixekizumab
Purity	>95%

SDS-PAGE image




Concentration	3.67mg/ml
Formulation	PBS buffer PH7.4
Source	CHO cells
Endotoxin level	Please contact with the lab for this information.
Note	For research use only .

Bioactivity

Description	<p>Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-</p>
-------------	---

to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Bioactivity



Alternative names	LY2439821
Specificity target name;species	IL17A [Homo sapiens]
Species	Humanized
Receptor identification	IgG4-kappa

Chemistry

MV

146158.0 Da

CAS

1143503-69-8

Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.